2022
Exports
$81.9kWorld Rnk 136 / 208
Flag Rnk 426 / 837
2022
PRODUCT COMPLEXITY IN Vaccines, blood, antisera, toxins and cultures
1.38Rnk 75 / 1025
2022
Imports
$32.6MWorld Rnk 138 / 225
Flag Rnk 43 / 1116
2022
ECONOMIC COMPLEXITY of Albania
-0.24Rnk 77 / 133

About

Exports In 2022, Albania exported $81.9k in Vaccines, blood, antisera, toxins and cultures, making it the 136th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 426th most exported product in Albania. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Albania are: Italy ($72.5k), Germany ($3.89k), Belgium ($1.46k), France ($1.37k), and Poland ($1.23k).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Albania between 2021 and 2022 were Italy ($5.35k), France ($1.26k), and Poland ($991).

Imports In 2022, Albania imported $32.6M in Vaccines, blood, antisera, toxins and cultures, becoming the 138th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 43rd most imported product in Albania. Albania imports Vaccines, blood, antisera, toxins and cultures primarily from: Switzerland ($10.2M), Belgium ($7.68M), Germany ($4.86M), Austria ($2.06M), and Slovenia ($1.91M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Albania between 2021 and 2022 were Switzerland ($9.53M), Austria ($548k), and Germany ($498k).

Latest Trends

Oct 2024

Subnational Monthly Trade

View
Flow
Y-AXIS SCALE

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

* Using January 2020 exchange rates when trade data is reported in local currency.

Explore Latest Trends

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Trade Balance

Color
EXPORTS (2022)$81.9k
IMPORTS (2022)$32.6M
NET TRADE (2022)-$32.6M

In 2022, Albania exported $81.9k in Vaccines, blood, antisera, toxins and cultures. The main destinations of Albania exports on Vaccines, blood, antisera, toxins and cultures were Italy ($72.5k), Germany ($3.89k), Belgium ($1.46k), France ($1.37k), and Poland ($1.23k).

In 2022, Albania imported $32.6M in Vaccines, blood, antisera, toxins and cultures, mainly from Switzerland ($10.2M), Belgium ($7.68M), Germany ($4.86M), Austria ($2.06M), and Slovenia ($1.91M).

Explore Visualizations

Export Destinations (2022)

Import Origins (2022)

Market Growth

Flow
THE FASTEST GROWING Vaccines, blood, antisera, toxins and cultures EXPORT MARKETS FOR Albania WERE (2021 - 2022):
Italy$5.35k (7.96%)
France$1.26k (1.14k%)
Poland$991 (416%)
THE FASTEST DECLINING MARKETS FOR THE EXPORT OF Vaccines, blood, antisera, toxins and cultures BY Albania WERE (2021 - 2022):
United States-$30.2k (-100%)
Netherlands-$25k (-99.5%)
Czechia-$1.21k (-99.7%)

Change in Exports by Market (2021 - 2022)

Market Concentration

View
Flow
Type
In 2022, Albania's main exporting competitors in Vaccines, blood, antisera, toxins and cultures were:
In 2022, Albania's main importing competitors in Vaccines, blood, antisera, toxins and cultures were:

Explore Visualizations

Trade Value of Vaccines, blood, antisera, toxins and cultures by Exporters

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALItaly+ $125k
TOP IMPORT POTENTIALGermany+ $5.11M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is Italy. With an export gap of $125k.   Vaccines, blood, antisera, toxins and cultures’s highest import potential is Germany with an import gap of $5.11M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with